Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025

Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025

DZD8586 demonstrated significant anti-tumor efficacy in heavily pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients with ORR of 84.2% DZD6008, a BBB-penetrant 4th generation EGFR TKI, showed encouraging and durable...

Dizal to Showcase Data in Hematologic Malignancies and Lung Cancer at ASCO 2025

Dizal to Showcase Data in Hematologic Malignancies and Lung Cancer at ASCO 2025

DZD8586 study results in B-cell non-Hodgkin lymphomas (B-NHLs) were selected for oral and poster presentations. The analysis in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after covalent or non-covalent BTK inhibitors and BTK...

Dizal Announces DZD8586 and DZD6008 Presentations at 2025 ASCO Annual Meeting

Dizal Announces DZD8586 and DZD6008 Presentations at 2025 ASCO Annual Meeting

SHANGHAI, April 1, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that results of its investigational drug...

menu
menu